JP5111725B2 - Pharmaceutical composition using suizenjina - Google Patents
Pharmaceutical composition using suizenjina Download PDFInfo
- Publication number
- JP5111725B2 JP5111725B2 JP2004307139A JP2004307139A JP5111725B2 JP 5111725 B2 JP5111725 B2 JP 5111725B2 JP 2004307139 A JP2004307139 A JP 2004307139A JP 2004307139 A JP2004307139 A JP 2004307139A JP 5111725 B2 JP5111725 B2 JP 5111725B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- suizenjina
- food
- pharmaceutical composition
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 11
- 230000003308 immunostimulating effect Effects 0.000 claims description 19
- 229960001438 immunostimulant agent Drugs 0.000 claims description 9
- 239000003022 immunostimulating agent Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013305 food Nutrition 0.000 description 23
- 239000000843 powder Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000003472 antidiabetic agent Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 229940126904 hypoglycaemic agent Drugs 0.000 description 9
- 238000009395 breeding Methods 0.000 description 8
- -1 patches Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 244000025254 Cannabis sativa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102100035793 CD83 antigen Human genes 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229940100486 rice starch Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940100445 wheat starch Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001341 hydroxy propyl starch Substances 0.000 description 2
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229940116317 potato starch Drugs 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000123865 Gynura bicolor Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 102000020006 aldose 1-epimerase Human genes 0.000 description 1
- 108091022872 aldose 1-epimerase Proteins 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、スイゼンジナの食品及び医薬組成物としての用途に関する。 The present invention relates to the use of suizenzina as food and pharmaceutical compositions.
スイゼンジナ(金時草)は学名をGynura bicolorといい、原産地は熱帯アジアである。我が国には18世紀頃に中国から伝わったとされている。和名は初期の頃の栽培地である熊本市の水前寺にちなんでつけられたとされている。学名のbicolorは、葉の表は緑色であるのに対して裏側が赤紫色であることから命名されたと考えられる。金沢市の特産野菜(加賀野菜)の一種で、葉の裏側の赤紫色(金時色)にちなんで金時草(キンジソウ)と呼ばれている。赤紫色は抗酸化活性成分であるアントシアニンに由来し、血圧降下作用を示すγ−アミノ酪酸(GABA)も得られている。 Suizenjina (Kinkikusa) is called Gynura bicolor, and its origin is tropical Asia. It is said that Japan was introduced from China around the 18th century. The Japanese name is said to have been named after Suizenji Temple in Kumamoto City, where it was cultivated in the early days. The scientific name “bicolor” is thought to have been named because the front of the leaves is green while the back side is reddish purple. It is a kind of special vegetable (Kaga vegetable) in Kanazawa city, and it is called Kintoso after the reddish purple (gold color) on the back side of the leaf. The reddish purple color is derived from anthocyanin, which is an antioxidant active ingredient, and γ-aminobutyric acid (GABA) that exhibits a blood pressure lowering action is also obtained.
スイゼンジナ又はその抽出物の薬理効果に関する報告はほとんどなく、免疫賦活作用、血糖降下作用については何ら報告されていない。 There are almost no reports on the pharmacological effects of suizenina or its extract, and no immunostimulatory action or hypoglycemic action has been reported.
本発明の目的は、スイゼンジナの乾燥粉末、抽出物又はその処理物を用いた食品及び医薬組成物を提供することにある。 An object of the present invention is to provide a food and a pharmaceutical composition using a dry powder of suizenina, an extract or a processed product thereof.
本発明は、以下の発明を包含する。
(1)スイゼンジナの乾燥粉末、抽出物又はその処理物を含有する食品。
(2)免疫賦活させるための前記(1)に記載の食品。
(3)血糖値を低下させるための前記(1)に記載の食品。
(4)抗肥満食品である前記(1)に記載の食品。
(5)体質改善させるための前記(1)に記載の食品。
(6)スイゼンジナの乾燥粉末、抽出物又はその処理物を含有する医薬組成物。
(7)スイゼンジナ由来で免疫賦活活性を示す物質を含有する免疫賦活剤。
(8)スイゼンジナの乾燥粉末、抽出物又はその処理物を含有する免疫賦活剤。
(9)食品に添加するための前記(7)又は(8)に記載の免疫賦活剤。
(10)スイゼンジナ由来で血糖降下活性を示す物質を含有する血糖降下剤。
(11)スイゼンジナの乾燥粉末、抽出物又はその処理物を含有する血糖降下剤。
(12)食品に添加するための前記(10)又は(11)に記載の血糖降下剤。
The present invention includes the following inventions.
(1) A food containing dry powder of suizenina, extract or processed product thereof.
(2) The food according to (1) above for immunostimulation.
(3) The food according to (1) above for reducing blood glucose level.
(4) The food according to (1), which is an anti-obesity food.
(5) The food according to (1) above for improving the constitution.
(6) A pharmaceutical composition containing a dry powder of suizenina, an extract or a processed product thereof.
(7) An immunostimulant containing a substance derived from suizendina and exhibiting immunostimulatory activity.
(8) An immunostimulant containing a dry powder of suizenzina, an extract or a processed product thereof.
(9) The immunostimulator according to (7) or (8) for addition to food.
(10) A hypoglycemic agent containing a substance derived from suizendina and exhibiting hypoglycemic activity.
(11) A hypoglycemic agent containing a dry powder of suizenina, an extract or a processed product thereof.
(12) The hypoglycemic agent according to (10) or (11) for addition to food.
本発明によれば、スイゼンジナの乾燥粉末、抽出物又はその処理物を含有し、免疫賦活作用及び血糖降下作用を有する食品及び医薬組成物を提供することができる。本発明の食品及び医薬組成物は、免疫賦活作用、血糖降下作用及び抗肥満作用を有することから、体質改善剤としても有用である。 ADVANTAGE OF THE INVENTION According to this invention, the foodstuff and pharmaceutical composition which contain the dry powder of a suizenjina, an extract, or its processed material and have an immunostimulatory effect and a hypoglycemic effect can be provided. Since the food and pharmaceutical composition of the present invention have an immunostimulatory action, a hypoglycemic action and an anti-obesity action, they are also useful as a constitution improving agent.
本発明においては、スイゼンジナは、乾燥粉末、抽出物又はその処理物として用いられる。抽出原料となるスイゼンジナは、全草、葉、あるいは根のいずれでもよいが、好ましくは全草が用いられる。 In the present invention, suizenjina is used as a dry powder, an extract or a processed product thereof. The suizenjina used as an extraction raw material may be whole grass, leaf, or root, but preferably whole grass is used.
本発明において、スイゼンジナ由来で免疫賦活活性を示す物質とは、スイゼンジナから得られるものであって、免疫能を活性化させるものであれば、特に制限はなく、例えば、スイゼンジナの抽出物、又はこれに分離、精製、単離等の各種処理の少なくとも1つを施したものであって免疫賦活活性を保持しているものをいう。 In the present invention, the substance that exhibits immunostimulatory activity derived from suizenjina is not particularly limited as long as it is obtained from suizenjina and activates its immunity, for example, an extract of suizenjina, or this And those that have been subjected to at least one of various treatments such as separation, purification, and isolation and that retain immunostimulatory activity.
また、スイゼンジナ由来で血糖降下活性を示す物質とは、スイゼンジナから得られるものであって、血糖値の上昇を抑制する活性を有するものであれば、特に制限はなく、例えば、スイゼンジナの抽出物、又はこれに分離、精製、単離等の各種処理の少なくとも1つを施したものであって血糖降下活性を保持しているものをいう。 Further, the substance exhibiting hypoglycemic activity derived from Suizenjina is not particularly limited as long as it is obtained from Suizenjina and has an activity of suppressing an increase in blood glucose level, for example, an extract of suizenjina, Or what applied at least 1 of various processes, such as isolation | separation, a refinement | purification, isolation, and this, and hold | maintains hypoglycemic activity.
抽出溶媒としては、水;アルコール類、例えばメタノール、エタノール、プロパノール、ブタノール;エステル類、例えば酢酸エチル等の酢酸エステル;エーテル類、例えばエチルエーテル、ジオキサン;ケトン類、例えばアセトン等が挙げられる。抽出物を一旦溶媒除去して乾燥物として用いる場合には、前述した任意の溶媒を単独で又は混合して用いることができる。一方、抽出物を溶媒に溶解した状態で用いる場合には、人体に対して有害な作用を示さない溶媒を用いる必要があり、この場合には、水、エタノール又はこれらの混合物を用いることが好ましい。抽出に際して、スイゼンジナの全草、葉、根等は、そのまま用いることができ、また乾燥後に破砕又は粉砕して溶媒との接触を高めることもできる。 Examples of the extraction solvent include water; alcohols such as methanol, ethanol, propanol and butanol; esters such as acetate such as ethyl acetate; ethers such as ethyl ether and dioxane; ketones such as acetone and the like. When the extract is once solvent-removed and used as a dried product, any of the above-described solvents can be used alone or in combination. On the other hand, when the extract is used in a state dissolved in a solvent, it is necessary to use a solvent that does not have a harmful effect on the human body. In this case, it is preferable to use water, ethanol, or a mixture thereof. . In the extraction, the whole plants, leaves, roots, etc. of suizenina can be used as they are, or can be crushed or pulverized after drying to enhance contact with the solvent.
スイゼンジナの全草、葉等の1kg当り溶媒2〜4Lで抽出する。抽出温度は、室温ないし溶媒の常圧下での沸点の範囲内であり、抽出時間は、抽出温度等により異なるが、好ましくは、室温の場合24〜30時間、溶媒の常圧下での沸点で行う場合0.5〜2時間である。 Extract with 2 to 4 L of solvent per 1 kg of Suizenjina whole grass, leaves, etc. The extraction temperature is within the range of room temperature to the boiling point of the solvent under normal pressure, and the extraction time varies depending on the extraction temperature and the like, but preferably at room temperature for 24 to 30 hours at the boiling point of the solvent under normal pressure. The case is 0.5 to 2 hours.
このようにして得られた抽出液は、必要に応じて、布、ステンレスフィルター、濾紙、濾過滅菌用フィルター等で濾過して不溶物、不純物等を除去して用いてもよい。また、濾過後の抽出液に、スプレードライ処理、フリーズドライ処理、超臨界処理等の処理を施してもよい。 The extract obtained in this manner may be used after removing it with a cloth, stainless steel filter, filter paper, filter sterilization filter or the like to remove insoluble matters, impurities, etc., if necessary. Moreover, you may give processes, such as a spray-dry process, a freeze-dry process, a supercritical process, to the extract after filtration.
スイゼンジナ乾燥粉末は、スイゼンジナの全草等の1kgを水洗後、温風乾燥機で90℃にて乾燥、粉砕して、粒径0.005〜0.1mmの粉末とする。 The dried suizenjina powder is a powder having a particle size of 0.005 to 0.1 mm, after washing 1 kg of all suizenjina grass, etc., and drying and pulverizing at 90 ° C. with a warm air dryer.
このようにして得られる乾燥粉末、抽出物又はその処理物は、そのまま本発明の食品、医薬組成物、免疫賦活剤及び血糖降下剤の有効成分として用いることができる。また、当該抽出物等をイオン交換クロマトグラフィー、ゲル濾過クロマトグラフィー、透析等の各種精製手段により処理し、更に活性を高めた処理物として用いてもよい。 The dry powder, extract or processed product thus obtained can be used as an active ingredient of the food, pharmaceutical composition, immunostimulant and hypoglycemic agent of the present invention as it is. Moreover, the said extract etc. may be processed by various purification means, such as ion exchange chromatography, gel filtration chromatography, and dialysis, and you may use as a processed material which heightened activity further.
本発明の食品、医薬組成物、免疫賦活剤及び血糖降下剤は、スイゼンジナの乾燥粉末、抽出物又はその処理物を公知の食品用担体又は医薬用担体と組合せて製剤化することができる。投与形態としては、特に制限はなく、必要に応じ適宜選択されるが、一般には錠剤、カプセル剤、顆粒剤、細粒剤、散剤、液剤、シロップ剤、懸濁剤、乳剤、エリキシル剤等の経口剤として使用される。また、本発明の医薬組成物、免疫賦活剤及び血糖降下剤は、注射剤、点滴剤、坐剤、吸入剤、経皮吸収剤、経粘膜吸収剤、貼付剤、軟膏剤等の非経口剤として使用してもよい。また、本発明の食品、免疫賦活剤及び血糖降下剤は、食品、チューインガム、飲料等に添加して、いわゆる特定保健用食品(例えば、体質改善用食品、免疫調節機能性食品、血糖降下性食品、抗肥満食品)等とすることもできる。 The food, pharmaceutical composition, immunostimulant, and hypoglycemic agent of the present invention can be formulated by combining a dried powder of suizenina, an extract or a processed product thereof with a known food carrier or pharmaceutical carrier. The dosage form is not particularly limited and is appropriately selected as necessary. In general, tablets, capsules, granules, fine granules, powders, solutions, syrups, suspensions, emulsions, elixirs, etc. Used as an oral agent. The pharmaceutical composition, immunostimulant and hypoglycemic agent of the present invention are parenteral agents such as injections, drops, suppositories, inhalants, transdermal absorption agents, transmucosal absorption agents, patches, ointments and the like. May be used as In addition, the food, immunostimulant and hypoglycemic agent of the present invention are added to foods, chewing gums, beverages, etc., so-called foods for specific health (for example, foods for improving constitution, immunomodulating functional foods, hypoglycemic foods , Anti-obesity food).
本発明の食品、医薬組成物、免疫賦活剤及び血糖降下剤の投与量は、患者の年令、体重、疾患の程度、投与経路により異なるが、経口投与では、スイゼンジナ抽出物、乾燥粉末の乾燥粉末として、通常1日5〜500mgであり、投与回数は、通常、経口投与では1日1〜3回である。 The dosage of the food, pharmaceutical composition, immunostimulant and hypoglycemic agent of the present invention varies depending on the patient's age, body weight, degree of disease and route of administration, but for oral administration, suizenina extract, dried powder dry As a powder, it is usually 5 to 500 mg per day, and the administration frequency is usually 1 to 3 times per day for oral administration.
経口剤は、例えばデンプン、乳糖、白糖、マンニット、カルボキシメチルセルロース、コーンスターチ、無機塩類等の賦形剤を用いて常法に従って製造される。 Oral preparations are produced according to a conventional method using excipients such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, and inorganic salts.
この種の製剤には、適宜前記賦形剤の他に、結合剤、崩壊剤、界面活性剤、滑沢剤、流動性促進剤、矯味剤、着色剤、香料等を使用することができる。 In this type of preparation, a binder, a disintegrant, a surfactant, a lubricant, a fluidity promoter, a corrigent, a colorant, a fragrance and the like can be appropriately used in addition to the above-mentioned excipients.
結合剤の具体例としては、結晶セルロース、結晶セルロース・カルメロースナトリウム、メチルセルロース、ヒドロキシプロピルセルロース、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルメチルセルロースフタレート、ヒドロキシプロピルメチルセルロースアセテートサクシネート、カルメロースナトリウム、エチルセルロース、カルボキシメチルエチルセルロース、ヒドロキシエチルセルロース、コムギデンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、デキストリン、アルファー化デンプン、部分アルファー化デンプン、ヒドロキシプロピルスターチ、プルラン、ポリビニルピロリドン、アミノアルキルメタクリレートコポリマーE、アミノアルキルメタクリレートコポリマーRS、メタクリル酸コポリマーL、メタクリル酸コポリマー、ポリビニルアセタールジエチルアミノアセテート、ポリビニルアルコール、アラビアゴム、アラビアゴム末、寒天、ゼラチン、白色セラック、トラガント、精製白糖、マクロゴールが挙げられる。 Specific examples of the binder include crystalline cellulose, crystalline cellulose / carmellose sodium, methylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carmellose sodium , Ethylcellulose, carboxymethylethylcellulose, hydroxyethylcellulose, wheat starch, rice starch, corn starch, potato starch, dextrin, pregelatinized starch, partially pregelatinized starch, hydroxypropyl starch, pullulan, polyvinylpyrrolidone, aminoalkyl methacrylate copolymer E, aminoalkyl METAKU Rate copolymer RS, methacrylic acid copolymer L, methacrylic acid copolymer, polyvinyl acetal diethylamino acetate, polyvinyl alcohol, gum arabic, gum arabic powder, agar, gelatin, white shellac, tragacanth, purified sucrose, macrogol.
崩壊剤の具体例としては、結晶セルロース、メチルセルロース、低置換度ヒドロキシプロピルセルロース、カルメロース、カルメロースカルシウム、カルメロースナトリウム、クロスカルメロースナトリウム、コムギデンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、部分アルファー化デンプン、ヒドロキシプロピルスターチ、カルボキシメチルスターチナトリウム、トラガントが挙げられる。 Specific examples of disintegrants include crystalline cellulose, methylcellulose, low-substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, croscarmellose sodium, wheat starch, rice starch, corn starch, potato starch, and partially pregelatinized. Starch, hydroxypropyl starch, sodium carboxymethyl starch, tragacanth can be mentioned.
界面活性剤の具体例としては、大豆レシチン、ショ糖脂肪酸エステル、ステアリン酸ポリオキシル、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンポリオキシプロピレングリコール、セスキオレイン酸ソルビタン、トリオレイン酸ソルビタン、モノステアリン酸ソルビタン、モノパルミチン酸ソルビタン、モノラウリン酸ソルビタン、ポリソルベート、モノステアリン酸グリセリン、ラウリル硫酸ナトリウム、ラウロマクロゴールが挙げられる。 Specific examples of surfactants include soybean lecithin, sucrose fatty acid ester, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate Sorbitan monopalmitate, sorbitan monolaurate, polysorbate, glyceryl monostearate, sodium lauryl sulfate, lauromacrogol.
滑沢剤の具体例としては、コムギデンプン、コメデンプン、トウモロコシデンプン、ステアリン酸、ステアリン酸カルシウム、ステアリン酸マグネシウム、含水二酸化ケイ素、軽質無水ケイ酸、合成ケイ酸アルミニウム、乾燥水酸化アルミニウムゲル、タルク、メタケイ酸アルミン酸マグネシウム、リン酸水素カルシウム、無水リン酸水素カルシウム、ショ糖脂肪酸エステル、ロウ類、水素添加植物油、ポリエチレングリコールが挙げられる。 Specific examples of lubricants include wheat starch, rice starch, corn starch, stearic acid, calcium stearate, magnesium stearate, hydrous silicon dioxide, light anhydrous silicic acid, synthetic aluminum silicate, dry aluminum hydroxide gel, talc, Examples thereof include magnesium aluminate metasilicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, sucrose fatty acid ester, waxes, hydrogenated vegetable oil, and polyethylene glycol.
流動性促進剤の具体例としては、含水二酸化ケイ素、軽質無水ケイ酸、乾燥水酸化アルミニウムゲル、合成ケイ酸アルミニウム、ケイ酸マグネシウムが挙げられる。 Specific examples of the fluidity promoter include hydrous silicon dioxide, light anhydrous silicic acid, dry aluminum hydroxide gel, synthetic aluminum silicate, and magnesium silicate.
また、本発明の食品、医薬組成物、免疫賦活剤及び血糖降下剤は、液剤、シロップ剤、懸濁剤、乳剤、エリキシル剤として投与する場合には、矯味矯臭剤、着色剤を含有してもよい。 In addition, the food, pharmaceutical composition, immunostimulant and hypoglycemic agent of the present invention contain a flavoring agent and a coloring agent when administered as a solution, syrup, suspension, emulsion, or elixir. Also good.
以下、実施例により本発明を具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention concretely, this invention is not limited to these Examples.
(製造例1)スイゼンジナ抽出物の調製
スイゼンジナの全草の1.5kg、あるいは乾燥した全草の150gを90〜100℃の熱水2〜4Lで1〜2時間抽出した。濾過により固形物を除いた抽出液を凍結乾燥あるいはスプレードライにかけて、約40gの抽出物を得た。
(Production Example 1) Preparation of suizenjina extract 1.5 kg of whole suizenjina grass or 150 g of dried whole grass was extracted with 2-4 L of hot water at 90-100 ° C for 1-2 hours. The extract from which solids were removed by filtration was freeze-dried or spray-dried to obtain about 40 g of extract.
(製造例2)スイゼンジナ乾燥粉末の調製
スイゼンジナの全草の15.32kgを水道水にて洗浄し、温風乾燥機で90℃にて4〜5時間乾燥し、乾燥品0.99kgを得た。スイゼンジナの乾燥品0.99kgを中型粉砕機を用いて室温、湿度75%の条件下粉砕し、粒径0.005〜0.1mm(平均粒径0.025mm)の乾燥粉末0.93kgを得た。
(Production Example 2) Preparation of dried suizendina powder 15.32 kg of whole suizendina grass was washed with tap water and dried at 90 ° C. for 4 to 5 hours with a hot air dryer to obtain 0.99 kg of a dried product. . 0.99 kg of dried Suizenjina product was pulverized using a medium pulverizer under conditions of room temperature and humidity of 75% to obtain 0.93 kg of dry powder having a particle size of 0.005 to 0.1 mm (average particle size of 0.025 mm). It was.
(実施例1)ヒト末梢血単球由来樹状細胞誘導能に基づく免疫賦活効果の評価
ヒト末梢血単核細胞を材料として用い、試料の添加による樹状細胞(DC)の誘導能を評価する。なお、ポジティブコントロールとしてピシバニールを用いる。評価法としては、活性化DCの表面抗原(CD80,CD83)をモノクローナル抗体を用いたフローサイトメトリーを用い解析した。
(Example 1) Evaluation of immunostimulatory effect based on ability to induce human peripheral blood monocyte-derived dendritic cells Using human peripheral blood mononuclear cells as materials, the ability to induce dendritic cells (DC) by adding samples is evaluated. . Note that picibanil is used as a positive control. As an evaluation method, the surface antigen (CD80, CD83) of activated DC was analyzed using flow cytometry using a monoclonal antibody.
(方法)
(1)材料
実験者自身の末梢血を材料として用いた。
(2)免疫賦活効果評価用の試料
(a)製造例1で得たスイゼンジナ抽出物。
(b)ポジティブコントロールとしてピシバニールを用いた。
(3)末梢血単核細胞(PBMC)の分離
ヘパリン加採血された全血検体からFicoll-Paque比重遠心法によりPBMCを分離した。
(4)末梢血単球由来のDCの誘導とその表面抗原の測定
PBMCを炭酸ガスインキュベーターで1時間処理し、単球に富む付着細胞分画を得た。得られた細胞をIL−4、GM−CSF 各々500U/mL存在下に5%ヒトAB血清加RPMI−1640中で培養した。培養には25cm2フラスコを用い、1フラスコ当り2×106個のディッシュ付着細胞を散布した。培養0〜6日の間毎日1回試料を加えた。7日目にコントロール及び試料を添加したフラスコから全てのDCを回収し、その表面抗原(CD80,CD83)をモノクローナル抗体を用いたフローサイトメトリーで解析した。
(Method)
(1) Material The experimenter's own peripheral blood was used as a material.
(2) Sample for evaluating immunostimulatory effect (a) Suizenina extract obtained in Production Example 1.
(B) Picibanil was used as a positive control.
(3) Separation of peripheral blood mononuclear cells (PBMC) PBMC was separated from a whole blood sample collected with heparin by Ficoll-Paque specific gravity centrifugation.
(4) Induction of DCs derived from peripheral blood monocytes and measurement of their surface antigens PBMCs were treated with a carbon dioxide incubator for 1 hour to obtain adherent cell fractions rich in monocytes. The obtained cells were cultured in RPMI-1640 supplemented with 5% human AB serum in the presence of 500 U / mL of IL-4 and GM-CSF. A 25 cm 2 flask was used for culture, and 2 × 10 6 dish-attached cells were sprayed per flask. Samples were added once daily for 0-6 days in culture. On the 7th day, all DCs were recovered from the flask containing the control and the sample, and the surface antigens (CD80, CD83) were analyzed by flow cytometry using a monoclonal antibody.
(結果)
マーカーとしてCD80、CD83及びCD86の3種の表面抗原を用い、ポジティブコントロールとしてのピシバニールと製造例1で得たスイゼンジナ抽出物との樹状細胞活性化を比較したところ、300mg/mLの濃度では両者同等の活性化を示した。結果を表1に示す。
(result)
Using three kinds of surface antigens CD80, CD83 and CD86 as markers, and comparing the activation of dendritic cells between Picibanil as a positive control and the suizenina extract obtained in Production Example 1, both were obtained at a concentration of 300 mg / mL. Equivalent activation was shown. The results are shown in Table 1.
前記の結果は、スイゼンジナ抽出物の免疫賦活作用は末梢血単球由来樹状細胞の誘導能(CD80の発現増強)及び成熟化(CD83の発現増強)の2面からなることを示す。 The above results indicate that the immunostimulatory action of the suizenina extract consists of two aspects: peripheral blood monocyte-derived dendritic cell inducibility (enhanced expression of CD80) and maturation (enhanced expression of CD83).
(実施例2)抗肥満試験
正常マウス(ICR)を用い、これに高脂肪・高カロリー飼料を摂取させて急性肥満を惹起させた。急性肥満モデルマウスに製造例1で得たスイゼンジナ抽出物を経口投与して、体重、飼料の摂取量、及び血中のグルコースレベルを調べた。
(Example 2) Anti-obesity test A normal mouse (ICR) was used, and a high-fat and high-calorie diet was ingested therein to induce acute obesity. The suizenjina extract obtained in Production Example 1 was orally administered to an acute obese model mouse, and the body weight, feed intake, and blood glucose level were examined.
(方法)
使用動物:ICRマウス(雄性、5週齢、日本チャールズリバー)
使用匹数:7〜10匹/群
マウスの群分け:3群(1:一般飼育飼料投与群(通常飼育ICR正常対照群、n=7)、2:高脂肪・高カロリー飼料投与群(肥満対照群、n=10)、3:高脂肪・高カロリー飼料にスイゼンジナ抽出物の経口投与群(n=10))。
(Method)
Animals used: ICR mice (male, 5 weeks old, Nippon Charles River)
Number of animals used: 7 to 10 / group of mice: 3 groups (1: General breeding feed administration group (normal breeding ICR normal control group, n = 7), 2: High fat / high calorie diet administration group (obesity) Control group, n = 10), 3: high-fat, high-calorie feed and orally administered suizenjina extract (n = 10)).
マウス飼育飼料
検体投与:製造例1で得たスイゼンジナ抽出物を100mg/kgとなるように精製水で調製し、体重10g当り0.1mLの用量になるように経口投与用のマウスゾンデを用いて2日に1回、強制経口投与した。検体は作り置きせずに、用時作製するとともに経口投与の時間は毎回20時に行った。なお、経口投与を毎日行わずに2日に1回にしたのはマウスに対するストレスを緩和することを目的としている。
飼育条件:マウスをマウス・ラット飼育用の木材チップを敷いた小口のプラスチックケージに5匹ずつ分け、25±2〜3℃の室温(湿度は不明)で飼育した。
給水:実験期間中の摂水は自由とし、摂水量の測定は行わなかった。なお、摂水は水道水(超軟水は下痢の原因となるので使用しなかった)とし給水ビンは2日おきに1回、交換した。
飼育方法:アニマルハンドリングはGLP規格に基づき、苦痛をなるだけ軽減するよう配慮して実験した。
Mice breeding feed sample administration: The suizenjina extract obtained in Production Example 1 was prepared with purified water so as to be 100 mg / kg, and a mouse sonde for oral administration was used at a dose of 0.1 mL per 10 g body weight. It was administered by oral gavage once every two days. Samples were prepared at the time of use without preparation, and oral administration was performed at 20:00 each time. In addition, the purpose of alleviating the stress on mice is that oral administration is not performed every day but once every two days.
Breeding conditions: Mice were divided into small plastic cages with wood chips for breeding mice and rats, and reared at room temperature of 25 ± 2 to 3 ° C. (humidity unknown).
Water supply: Water consumption was free during the experiment, and water consumption was not measured. The drinking water was tap water (super soft water was not used because it causes diarrhea), and the water bottle was changed once every two days.
Breeding method: Animal handling was conducted based on the GLP standard with consideration given to reducing pain as much as possible.
前記に従って用意したマウスについて、5匹当り100g前後の飼料を与えて飼育を開始した。次いで、あらかじめ計測していたマウス体重当りに換算した検体を経口投与した。なお、体重測定と経口投与、及び餌の摂取量の計測は、マウスの活動が活発化する19時以降に行い、経口投与は20時を目標に行った。経口投与開始から毎日、同じ時間帯にケージのステンレス網に残存する飼料の正確な重量とマウス個々の体重を計測し、これを17日間行った。飼育日数が進むにつれて減量する飼料は4日1回、新しい飼料と交換した。 The mice prepared according to the above were fed with about 100 g of feed per 5 mice and started breeding. Subsequently, the sample converted per mouse weight measured in advance was orally administered. In addition, the body weight measurement, oral administration, and measurement of food intake were performed after 19:00 when the activity of the mouse was activated, and oral administration was performed at 20:00. Every day from the start of oral administration, the exact weight of the food remaining in the stainless steel cage and the body weight of each mouse were measured at the same time period, and this was performed for 17 days. The feed reduced in weight as the breeding days progressed was replaced with fresh feed once every 4 days.
採血:17日間の実験終了後に、マウスをエーテル麻酔下に心臓から全身血を採取し、遠心後に血清を得て−80℃に保存した。なお、血清採取はヘパリン化をしないで行った。
血中のグルコース含量の測定:前記の方法に準じて得られた血清について、「グルコースCII−テストワコー(和光純薬社製)(ムタロターゼ・GOD法)」を用い、マニュアルにしたがって測定した。グルコース含量は何れもmg/dLで表示した。
データ解析:体重の比較増減、飼料摂取量、グルコース含量は平均値±標準誤差で表した。有効性の判定は対照群(正常あるいは肥満対照群)と検体投与群との間で薬理学的な有意差検定(ANOVA及びダンネットのt検定)を行い、5%未満の危険率を有意差ありと判断した。
Blood collection: At the end of the 17-day experiment, mice were collected from the heart under ether anesthesia, and serum was obtained after centrifugation and stored at -80 ° C. Serum was collected without heparinization.
Measurement of blood glucose content: Serum obtained according to the above method was measured according to the manual using "Glucose CII-Test Wako (manufactured by Wako Pure Chemical Industries) (Mutarotase GOD method)". All glucose contents are expressed in mg / dL.
Data analysis: Comparison of increase / decrease in body weight, feed intake, and glucose content were expressed as mean ± standard error. Effectiveness is determined by performing a pharmacological significant difference test (ANOVA and Dunnett's t-test) between the control group (normal or obese control group) and the sample administration group. Judged that there was.
(結果)
高脂肪・高カロリー飼料の摂取は、正常マウスにおいて著しい体重の増加と体内脂肪の増加と血糖値の上昇をもたらすことが明らかになった。このモデルにおいて、製造例1で得たスイゼンジナ抽出物を100mg/kgの用量でマウスに経口投与することにより、餌の摂取量が有意に増加するにも拘わらず、体重の増加量は高脂肪・高カロリー飼料のみの投与群に比較して低く推移した。実験終了日に採血した際の血糖値のレベルは、スイゼンジナ抽出物の投与により有意に減少した。結果を表2に示す。
(result)
Ingestion of high-fat and high-calorie diet has been shown to cause significant weight gain, increased body fat, and increased blood glucose levels in normal mice. In this model, the dose of 100 mg / kg orally administered to a mouse at a dose of 100 mg / kg orally obtained from Suizenjina extract was significantly increased in weight, but the increase in body weight was high. It was lower than that of the high calorie diet only group. The blood glucose level when blood was collected on the end of the experiment was significantly decreased by administration of the suizenzina extract. The results are shown in Table 2.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004307139A JP5111725B2 (en) | 2004-10-21 | 2004-10-21 | Pharmaceutical composition using suizenjina |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004307139A JP5111725B2 (en) | 2004-10-21 | 2004-10-21 | Pharmaceutical composition using suizenjina |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012128063A Division JP5593349B2 (en) | 2012-06-05 | 2012-06-05 | Hypoglycemic agent using suizenjina |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006117584A JP2006117584A (en) | 2006-05-11 |
| JP5111725B2 true JP5111725B2 (en) | 2013-01-09 |
Family
ID=36535818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004307139A Expired - Fee Related JP5111725B2 (en) | 2004-10-21 | 2004-10-21 | Pharmaceutical composition using suizenjina |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5111725B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4677523B2 (en) * | 2006-04-25 | 2011-04-27 | 石川県 | Kintokusa processing method, Kintokusa active ingredient extract and products containing it |
| JP2008174459A (en) * | 2007-01-16 | 2008-07-31 | Maruzen Pharmaceut Co Ltd | Anti-aging agent, external preparation for skin and food and drink for beauty |
| JP5070361B1 (en) * | 2012-02-15 | 2012-11-14 | 株式会社奄美大島開運酒造 | Method for producing solder GABA extract |
| JP5137220B1 (en) * | 2012-02-15 | 2013-02-06 | 株式会社奄美大島開運酒造 | Method for producing solder anthocyanin pigment extract |
| JP6619153B2 (en) * | 2015-05-15 | 2019-12-11 | 株式会社 アルマード | Green juice |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1589294A (en) * | 1976-09-08 | 1981-05-13 | Inverni Della Beffa Spa | Pharmaceutical compositions containing anthocyanidines |
| JPH11246396A (en) * | 1998-02-27 | 1999-09-14 | Shiseido Co Ltd | Immunopotentiator |
| JP2000212092A (en) * | 1999-01-27 | 2000-08-02 | Yanai Yoshiaki | Antivirus and antibacterial agent |
| JP2003252766A (en) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | Anti-obesity and / or anti-diabetic agent containing cyanidin 3-glucoside as an active ingredient |
| JP2004173546A (en) * | 2002-11-26 | 2004-06-24 | Etsuko Aoki | Soup |
-
2004
- 2004-10-21 JP JP2004307139A patent/JP5111725B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006117584A (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5313201B2 (en) | Drugs for the prevention or treatment of debilitating diseases | |
| JP5856728B2 (en) | Composition for oral administration or external use comprising polyphenol, and use thereof | |
| KR101634002B1 (en) | Composition for Immunological Enhancement Comprising Fermentation Product of Garlic and Preparing Method Thereof | |
| EP3831399A1 (en) | Anti-norovirus agent | |
| JP5111725B2 (en) | Pharmaceutical composition using suizenjina | |
| CN117229340B (en) | Active substances in black goji berries and their applications | |
| JP2005082509A (en) | Glucose level rise inhibitor and AGE production inhibitor | |
| JP2011105627A (en) | Anti-stress composition containing extracted fraction of lily bulb | |
| JP5593349B2 (en) | Hypoglycemic agent using suizenjina | |
| JP2004115434A (en) | Diabetes medicine | |
| KR102559627B1 (en) | A composition for preventing bone disease and improving bone function, using Lactobacillus fermented pumpkin tendril extract and manufacturing method thereof | |
| JP6915774B2 (en) | Testosterone increaser | |
| JP4720504B2 (en) | Plant seed extract composition and method for producing the same | |
| JP2009184940A (en) | Therapeutic agent | |
| CN1652805A (en) | An herbal composition for the treatment and remedy of bronchial respiratory difficulties | |
| JP2011074062A (en) | Anti-i type allergic agent | |
| JP4665152B2 (en) | Bone metabolism improver using Hinata summer oranges | |
| TW202313084A (en) | Use of tagetes erecta extract for preparing composition for reducing blood uric acid concentration wherein the tagetes erecta extract has the feature of having non-toxicity and high anti-oxidation capability for giving consideration to both effectiveness and safety | |
| JP2009161526A (en) | Treating agent | |
| JP2010173980A (en) | Agent for preventing or improving hyperuricemia | |
| CN1857424A (en) | Compound Chinese medicine preparation and its preparing process and quality control method | |
| JP2008106018A (en) | Maitake-derived substance having anti-influenza virus activity and method for producing the same | |
| JP5331046B2 (en) | Bioactive substances derived from peanut germ | |
| WO2005044290A1 (en) | Glucose absorption inhibitor and process for producing the same | |
| JP2004217558A (en) | Antitumor agent using processed peanut |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071016 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20071016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071102 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110425 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120201 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120605 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120726 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120911 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121010 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20181019 Year of fee payment: 6 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5111725 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |